JanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic Pain

The Broad Patent Coverage is a Major Milestone for the Commercial Success of Jan123 LAS VEGAS, Aug. 29, 2023 /PRNewswire/ — JanOne (Nasdaq: JAN), the visionary biotech company dedicated to discovering non-addictive treatments for pain, as well as causes of pain, has earned a US patent…